Additionally, knockdown of PLCG2 potentiated the efficacy of anti-PD-1 therapy for CRC, and targeted inhibition of PLCG2 in combination with immune checkpoint blockade (ICB) therapy might be an effective strategy to improve the immunotherapy response and survival of CRC patients. The gene discussed is PDCD1; the disease is colorectal carcinoma.